Positron emission tomography/computed tomography is a hybrid nuclear medicine imaging technique that helps radiologists spot abnormal metabolic activity. PET/CT is commonly used to diagnose cancers, heart diseases and certain brain disorders, among other conditions.
There are numerous radiotracers specifically designed to identify prostate cancer, but experts say one may be superior to the others at both the patient and lesion level.
The new appropriate use criteria define 17 specific clinical scenarios, guiding providers on situations when amyloid or tau imaging are and are not appropriate.
Reducing certain treatments by around 25% and 50% still achieves promising PSA response rates, but reduces some of the unwanted side effects of therapy, like dry mouth.
That’s according to new PET imaging that shows the presence of activated T cells in the brain, spinal cord, gut and lung tissues of individuals who have recovered from COVID.
Experts recently uncovered strong associations between reports of memory loss from patients' peers/loved ones and the presence of tau tangles on imaging.
An AI-aided way has emerged to confidently select dementia patients who are likely to benefit from amyloid-PET imaging while appropriately de-selecting patients for whom the costly exam would probably be unhelpful.
Smaller health systems are increasingly moving into this realm. Tim Kearns, director of marketing and healthcare IT, Konica Minolta Imaging USA, explains the implications.
